financetom
Business
financetom
/
Business
/
Domino's Pizza posts quarterly sales miss on muted fast-food demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Domino's Pizza posts quarterly sales miss on muted fast-food demand
Jul 18, 2024 3:52 AM

(Reuters) -Domino's Pizza fell short of estimates for quarterly same-store sales on Thursday, as inflation worries discouraged U.S. consumers, particularly in the lower-income group, from eating out or ordering in, sending its shares down 11% in premarket trading.

Sequentially slower growth in food services in June showed consumers were still looking to stretch their budgets as they recovered from high inflation, despite a better-than-expected overall U.S. retail sales report signaling economic resilience.

Domino's U.S. same-store sales growth of 4.8% in the quarter fell just short of expectations of 4.91% growth, according to LSEG data.

The company has been catering to consumers looking for cheaper options through its refreshed loyalty program in the U.S. as well as several offers to draw in customers.

Analysts, however, had expected tougher competition for Domino's this quarter, as fast-food peers also ramped up deals and promotions on their menu items.

Still, lower supply-chain costs and resilience in its same-store sales in the U.S. helped the world's largest pizza maker earn a profit of $4.03 per share, compared with market expectations of $3.68.

"We had positive order counts in our delivery and carry-out businesses, and across all income cohorts. Our strategy is resonating with customers," said Russell Weiner, Domino's chief executive officer.

Domino's reported total revenue of $1.10 billion in the second quarter, roughly in line with estimates.

The company maintained its long-term outlook of more than 7% annual global retail sales growth.

However, Domino's suspended its long-term target of 1,100 global net stores after its Australia-based master franchise said earlier this week it was closing low-volume stores in Japan and France.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Genuine Parts Q4 Earnings: Beats Street View, Industrial Sales Slump, Dividend Boost And More
Genuine Parts Q4 Earnings: Beats Street View, Industrial Sales Slump, Dividend Boost And More
Feb 18, 2025
Genuine Parts Co ( GPC ) shares are trading higher in premarket on Tuesday. The company reported fourth-quarter revenue growth of 3.3% year-on-year to $5.77 billion, beating the analyst consensus estimate of $5.71 billion. The increase was driven by a 3.2% benefit from acquisitions, a net 0.6% favorable impact of foreign currency and other, partially offset by a 0.5% decrease...
Sector Update: Consumer Stocks Mixed Pre-Bell Tuesday
Sector Update: Consumer Stocks Mixed Pre-Bell Tuesday
Feb 18, 2025
09:11 AM EST, 02/18/2025 (MT Newswires) -- Consumer stocks were mixed pre-bell Tuesday with the Consumer Staples Select Sector SPDR Fund ( XLP ) down 0.1% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) 0.4% higher recently. Conagra Brands ( CAG ) shares were over 5% lower after the company said it now expects fiscal 2025 adjusted...
ProPhase Labs Appoints Stu Hollenshead as Chief Operating Officer
ProPhase Labs Appoints Stu Hollenshead as Chief Operating Officer
Feb 18, 2025
09:14 AM EST, 02/18/2025 (MT Newswires) -- ProPhase Labs ( PRPH ) said Tuesday it has appointed Stu Hollenshead as chief operating officer. Hollenshead will continue to serve as chief executive officer of digital platform 10PM Curfew, ProPhase added. Shares of the company rose 20% in recent premarket activity. ...
Gilead Sciences Says New Drug Application for Lenacapavir to Prevent HIV Accepted by FDA
Gilead Sciences Says New Drug Application for Lenacapavir to Prevent HIV Accepted by FDA
Feb 18, 2025
09:14 AM EST, 02/18/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday that the US Food and Drug Administration has accepted its new drug application submissions for lenacapavir for the prevention of HIV as pre-exposure prophylaxis. The biopharmaceutical company said the FDA will review the applications under priority review and has assigned a Prescription Drug User Fee Act...
Copyright 2023-2026 - www.financetom.com All Rights Reserved